Aldosterone ELISA

Key Features and Values
  • Suitable for serum, plasma and urine samples to simplify inclusion into the labs normal routine sample type
  • Highly sensitive assay with low limit of detection to allow detection of low levels of aldosterone
Product Description

The Aldosterone ELISA is intended for the quantitative determination of Aldosterone in human serum, plasma or urine  and is intended for laboratory use only. Results are to be used in conjunction with other clinical and laboratory data to assist in the clinical assessment of hypertension related syndromes.

Scientific Description

Aldosterone is a steroid hormone produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. It plays a primary role in the regulation of sodium and potassium balance in the blood.  Aldosterone secretion is stimulated primarily via the renin angiotensin-aldosterone system (RAAS). The production of renin is stimulated when there is a reduction in renal perfusion pressure, reduction in plasma volume and a negative sodium balance.  Renin cleaves Angiotensinogen into Angiotensin I which ultimately leads to the production of Angiotensin II via angiotensin converting enzyme.  Angiotensin II acts on the vascular system causing vasoconstriction as well as stimulating the adrenal cortex to secrete aldosterone.

Aldosterone acts on mineralocorticoid receptors within the principal cells of the distal tubule to increase reabsorption of sodium and chloride and decrease reabsorption of potassium and hydrogen.  Aldosterone measurements are used in the diagnosis and treatment of primary aldosteronism1 (PA), hypertension caused by primary aldosteronism, selective hyperaldosteronism, edematous states and other conditions of electrolyte balance.

PA is a collective term for a group of disorders whereby aldosterone production is unsuitably high for the circulating sodium level independent of angiotensin II and potassium levels and its production cannot be reduced by sodium loading2.  Patients with PA have an increased risk of cardiovascular events, organ (heart and kidney) damage compared with those having essential hypertension and a general population3.

Prevalence of PA in hypertensive patients is estimated to be >5% and perhaps up to 10%2; within these groups, there is an increased prevalence of metabolic syndrome, diabetes and osteoporotic fractures3.

Publications

1. Funder JW et al. Case Detection, Diagnosis and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J. Clin Endocrinol. Metab. September 2008 93 (9) 2266-3281.
2. Funder JW, Carey RM, Mantero F, Hassan Murad M, Reincke M, Shibata H, Stowasser M, Young WF.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.  J Clin Endocrinol Metab, Volume 101, Issue 5, 1 May 2016, Pages 1889–1916
3. Williams TA, Reincke M.  Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited European Journal of Endocrinology (2018) 179, R19–R29

Download
Please enter your email address to download the DKO053-Aldosterone-IFU.pdf
Code: DKO053
Clinical Area:
Incubation: 60+20 min
Sensitivity: N/A
Specificity: N/A
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum, SST, plasma (lithium / sodium heparin, EDTA), urine
Sample Volume: 50 μL serum / plasma or 250 μL urine
Assay Range: 41.5 - 2000 pg/mL